Nutriband receives FDA feedback on abuse deterrent fentanyl patch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- S&P 500, Dow rise after Warsh says inflation risks have eased
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil falls as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Taiwan prosecutors detain Super Micro employees over chip exports
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
October 28, 2025 7:00 AM EDTNutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA FENTANYL (abuse deterrent transdermal system) through commercialization.
Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.
ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB)(NASDAQ: NTRBW), a company engaged in the development of prescription transdermal... More
